

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
4 November 2004 (04.11.2004)

PCT

(10) International Publication Number  
**WO 2004/093951 A1**

(51) International Patent Classification<sup>7</sup>: **A61M 15/00**,  
A61B 5/097

(21) International Application Number:  
PCT/GB2004/001714

(22) International Filing Date: 16 April 2004 (16.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0308771.5 16 April 2003 (16.04.2003) GB

(71) Applicant (for all designated States except US): **LOUGHBOROUGH UNIVERSITY ENTERPRISES LIMITED** [GB/GB]; Finance Office, Loughborough University, Loughborough, Leicestershire LE11 3TU (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SMITH, Peter, Richard** [GB/GB]; Loughborough University, Loughborough, Leicestershire LE11 3TU (GB). **KUSMARTSEVA, Olga** [GB/GB]; Loughborough University, Loughborough, Leicestershire LE11 3TU (GB).

(74) Agent: **HIGGIN, Paul**; Swindell & Pearson, 48 Friar Gate, Derby DE1 1GY (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **DEVICE FOR PULMONARY DRUG DELIVERY**



(57) Abstract: A method of assessing the effectiveness of pulmonary drug delivery, comprising the steps of: a) providing a drug into an air flow past a sensor comprising a radiation source and a radiation detector; b) detecting, at the radiation detector, incident radiation over a period of time as a measurement profile; c) quantifying at least one characteristic of the shape of a measurement profile; and d) producing an indication of the effectiveness of pulmonary drug delivery based upon the at least one quantified characteristic.

3/pats  
JC20 Rec'd PCT/PTO 14 OCT 2005

## DEVICE FOR PULMONARY DRUG DELIVERY

5           Embodiments of the present invention relate to pulmonary drug delivery. It particular they relate to apparatus and methods for the assessment of the effectiveness of pulmonary drug delivery.

10           The assessment of the effectiveness of a drug for pulmonary delivery is currently carried out in the laboratory using a twin stage impinger (TSI) apparatus. This apparatus draws the drug through a convoluted passage using a vacuum pump at a high flow rate for a reasonably long period e.g. 60l/min for 5 seconds. The convoluted passage has a first stage at a first sharp bend for capturing large drug particles in liquid, and a second stage for  
15           capturing fine drug particles in liquid. The liquid at the first stage is analysed to determine the mass of large particles of the drug captured there. The liquid at the second stage is analysed to determine the mass of fine particles of the drug captured there.

20           The effectiveness of a pulmonary drug depends upon its fine particle mass. This represents the amount of drug which is of the correct size (e.g. 0.5 to 6  $\mu\text{m}$ ) to reach deep within the lung and have a desirable physiological effect on a user. The drug particles that are greater in size than fine particles tend to be absorbed into a user's digestion system, which may cause side  
25           effects. The total mass of drug delivered when compared to the fine particle mass, indicates the efficiency of the drug delivery to the lung. When it is expressed as the ratio of the fine particle mass to the total dose mass, it is referred to as the fine particle fraction.

30           There are several disadvantages associated with the TSI procedure.

It is a difficult and time intensive procedure and may take a day to complete a single assessment. It may therefore take weeks or months to obtain enough data to determine statistical variance of the drug delivery process.

5

Another disadvantage is that the apparatus does not necessarily give results that are representative of actual drug delivery in vivo. The apparatus uses an air flow rate (e.g. 60l/min) that is not necessarily representative of particular human's breath in-take and for a period of time (5s) longer than a normal breath in-take.

10

Another disadvantage is that the apparatus tests the delivery properties of the drug independently of the user for whom the drug is intended.

15

It would be desirable to provide an improved assessment procedure.

According to a first aspect of the present invention there is provided a method of assessing the effectiveness of pulmonary drug delivery, comprising the steps of: a) providing a drug into an air flow past a sensor comprising a radiation source and a radiation detector; b) detecting, at the radiation detector, incident radiation over a period of time as a measurement profile; c) quantifying at least one characteristic of the shape of a measurement profile; and d) producing an indication of the effectiveness of pulmonary drug delivery based upon the at least one quantified characteristic.

20

25

The indication indicates how successful the drug delivery was i.e. the degree of success, and not whether drug delivery did or did not occur. It is typically a quantitative measure of the effectiveness of drug delivery.

30

There is also provided a measurement device for assessing the effectiveness of pulmonary drug delivery, comprising: a conduit through which air carrying a cloud of drug particles can flow during drug delivery; a radiation

source for providing radiation into the conduit; a radiation detector for detecting radiation from the conduit over a period of time as a measurement profile; and a processor operable to quantify one or more

- 5 characteristics of the shape of a measurement profile and to produce an indication of the effectiveness of pulmonary drug delivery based upon the quantified characteristic(s).

According to a second aspect of the invention there is provided a  
10 method of assessing the effectiveness of pulmonary drug delivery, comprising the steps of: recording, during a drug delivery, the output of a first radiation detector against time as a first measurement profile; recording, during the same drug delivery, the output of a second radiation detector against time as a second measurement profile; and processing the first and second  
15 measurement profiles to produce an indication of the effectiveness of pulmonary drug delivery.

There is also provided a measurement device for assessing the effectiveness of pulmonary drug delivery, comprising: a conduit through which  
20 air carrying a cloud of drug particles can flow during drug delivery; a radiation source for providing radiation into the conduit; a first radiation detector for detecting radiation from the conduit over a period of time as a first measurement profile; a second radiation detector for detecting radiation from the conduit over the period of time as a second measurement profile; and a  
25 processor operable to produce an indication of the effectiveness of pulmonary drug delivery based upon the first and second measurement profiles.

Embodiments of these aspects of the invention consequently provide a faster assessment procedure. This allows information on the statistical  
30 variance of the effectiveness of pulmonary drug delivery to be produced.

The air flow may be created by a person or a breathing simulator. Embodiments of the invention consequently provide an assessment

5 procedure that is representative of in vivo drug delivery and can take into account the person for whom the drugs are intended.

The measurement device can be attached to or integrated within an actual drug delivery device. Embodiments of the invention consequently provide an assessment procedure that takes into account the device used in  
10 situ for drug delivery.

According to a third aspect of the present invention there is provided a drug delivery device for providing a drug dose to a user in a plurality of separate drug deliveries, comprising: a drug metering means for releasing a  
15 controlled amount of drug for each drug delivery; a conduit through which air carrying a cloud of drug particles can flow; a radiation source for providing radiation into the conduit; a first radiation detector for detecting radiation from the conduit during a on-going drug delivery as a first measurement profile; and control means operable to control the drug metering means, for a  
20 subsequent drug delivery, in dependence upon at least the first measurement profile.

For a better understanding of the present invention reference will now be made by way of example only to the accompanying drawings in which:

25 Fig. 1 illustrates an assessment system for the rapid assessment of pulmonary drug delivery;

Fig. 2 illustrates a typical measurement profile;

Fig. 3 illustrates an alternative embodiment of the assessment system;

Fig. 4 illustrates a first measurement profile M1 and a second  
30 measurement profile M2 for a single drug delivery; and

Fig. 5 illustrates an adaptive- multi-dose drug delivery device.

Fig. 1 illustrates an assessment system 10 for the rapid assessment of in vivo pulmonary drug delivery. The system 10 comprises in axial flow series

5 a drug delivery device 12 including drug 14 for pulmonary delivery, a measurement device 20 and a physiological actuator 16. A flow of air F is drawn by the physiological actuator 16 from the drug delivery device 12, through the measurement device 20. A seal may be required at the interface between the drug delivery device 12 and the measurement device 20 and a seal may be required between the physiological actuator 16 and the measurement device 20.

The air flow F created by the physiological actuator 16, may aerosolises drug agglomerates in the air flow F and create a cloud of drug particles or the air flow F may draws an already existing aerosol cloud into the lung. The size of the particles and the distribution of particles within the cloud change as the cloud moves in the air flow F.

The effectiveness of a pulmonary drug depends upon its fine particle mass. This represents the amount of drug which is of the correct size (e.g. 0.5 to 6  $\mu\text{m}$ ) to reach deep within the lung and have a desirable physiological effect on a user. The drug particles that are greater in size than fine particles tend to be absorbed into a user's digestion system, which may cause side effects. The total mass of drug delivered when compared to the fine particle mass, indicates the efficiency of the drug delivery to the lung. When it is expressed as the ratio of the fine particle mass to the total dose mass, it is referred to as the fine particle fraction.

Aerosolised particle clouds scatter and absorb radiation according to the cloud composition, particularly the particle concentration and particle size distribution within the cloud. The system 10 is arranged to quantitatively assess the effectiveness of pulmonary drug delivery from a measurement

profile that indicates how detected radiation varies as the drug cloud passes between a radiation source and a radiation detector.

5 The drug for pulmonary delivery may be in any formulation including dry or liquid form or formulated as a solution/suspension with a solvent.

10 The drug delivery device 12 is a real pulmonary drug delivery device. It could be a currently marketed device or a new design of device intended for the market. Examples of the possible types of suitable pulmonary drug delivery devices include: metered dose inhalers, dry powder inhalers, nebulizers, single breath liquid systems, and metered solution inhalers.

15 The physiological actuator may be provided by a breath in-take of a person or by the operation of a breathing simulator.

20 The measuring device 20 includes a straight optically translucent tube 22 connected between the output of the drug delivery device 12 and the physiological actuator 16. The tube 22, in this example, has a 21 mm internal diameter and a fixed length of 60 mm. In other embodiments the tube 22 may have an internal diameter up to 30mm and a fixed length of between 5 and 200mm.

25 The measuring device also comprises a sensor 24 that is exterior to the tube 22, a processor connected to the sensor 24, a memory 27 and an output 29.

30 The sensor 24 includes a radiation source 25 and a radiation detector 26 lying in a plane perpendicular to the longitudinal axis of the tube 22 and the flow direction F. In this example, the sensor 24 operates by obscuration of light and the light source 25 and light detector 26 are positioned diametrically opposite each other. In other embodiments, the sensor 24 operates by light scattering and the source and detector are positioned in the same plane but

the detector is not positioned in the 'line-of-sight' of the light source so that it detects light at a predetermined scattering angle.

5 The processor 28 is programmed to record, during a drug in-take from the drug delivery device 12 by the physiological actuator 16, real-time data

from the sensor 24 in the memory 27. The real-time data is a measurement profile of how the detected radiation varies with time.

10 The processor 28 may start recording data in response to user input. For example, a button of a user interface of the measurement device 20 could be depressed to start recording. Alternatively, the processor 28 could start recording automatically in response to a detection of the start of the in-take procedure. For example, a flow detector could be positioned upstream of the  
15 sensor 24, and the processor 28 could detect when the detected flow rate exceeds a predetermined threshold.

A typical measurement profile is illustrated in Fig. 2. It records how the output M of the detector 26 varies with time as a drug cloud passes between  
20 the source 25 and detector 26. The inventors have determined how the shape of the measurement profile is sensitive to particle concentration and particle size distribution within the drug cloud.

The processor 28 is programmed to automatically process, in situ, the  
25 recorded measurement profile to assess the pulmonary drug delivery from the drug in-take in real-time. The processor 28 quantifies characteristics of the shape of the measurement profile and produces a quantified indication of, for example, the dose delivered, the fine particle dose delivered and the fine particle fraction delivered based upon the quantified characteristics. The  
30 results of the processing are provided to output 29, which could for example be a display.



The processing of the measurement profile starts with the fitting of a mathematical function  $P$  to the measurement profile. The function  $P$  is the sum of two parts: a dose function  $P_{\text{dose}}$  and a level transition (  $\_ /$  ) residual function  $P_{\text{residual}}$ .

5

Quantitative values of parameters characterising the shape of the measurement profile are extracted from the fitted dose function  $P_{\text{dose}}$  and from the fitted residual function  $P_{\text{residual}}$ .

10

The characteristic parameters may include:

a) The width  $W$  of the dose function  $P_{\text{dose}}$ , for example, the full width at half maximum. This is a time.

b) The maximum amplitude  $A$  of the dose function  $P_{\text{dose}}$ ,

15

c) The length  $L$  of the dose function  $P_{\text{dose}}$

d) The asymmetry of the dose function  $P_{\text{dose}}$

e) The deviation of the actual measurement profile from the fitted mathematical function  $P$

f) The height  $H$  of the residual function  $P_{\text{residual}}$ .

20

It has been determined by the inventors that the value of the maximum amplitude  $A$  of the dose function  $P_{\text{dose}}$  is correlated to the fine particle mass of the measured pulmonary drug cloud. Therefore, the quantitative value of the maximum amplitude  $A$  gives a quantitative indication of the fine particle mass in non-SI units. The memory 27 may store calibration data, which allows the processor 28 to convert the quantitative indication to a mass value in SI units.

25

It has been determined by the inventors that the value of the dose function  $P_{\text{dose}}$ , integrated over the width  $W$  is correlated to the total dose mass of the measured pulmonary drug cloud. Therefore, the quantitative value of the integral gives a quantitative indication of the dose mass in non-SI

30

units. The memory 27 may store calibration data, which allows the processor 28 to convert the quantitative indication to a mass value in SI units.

5 It has been determined by the inventors that the value of the maximum amplitude  $A$  of the dose function  $P_{\text{dose}}$  divided by the value of the dose function  $P_{\text{dose}}$  integrated over the width  $W$ , is correlated to the fine particle

fraction of the measured pulmonary drug cloud. Therefore, the quantitative value of the fraction gives a quantitative indication of the fine particle fraction  
10 in non-SI units. The memory 27 may store calibration data that allows the processor 28 to convert the quantitative indication to standard units.

The inventors have also determined that the length  $L$  is correlated to the pulmonary drug cloud volume and length, the asymmetry of the dose  
15 function  $P_{\text{dose}}$  is correlated to drug delivery cloud asymmetry, the deviation of the measurement profile from the fitted function  $P$  is correlated to the cloud homogeneity and that the height  $H$  of the residual function  $P_{\text{residual}}$  is correlated to the drug dose that is lost by adhering to the side walls of the passage through which the drug is delivered.

20

Thus, the quantitative values of parameters characterising the shape of the measurement profile extracted from the fitted curve  $P$ , the fitted dose function  $P_{\text{dose}}$  and from the fitted residual function  $P_{\text{residual}}$  may be used by the processor 28 to provide quantitative indications of the efficiency of the drug  
25 delivery process and/or of the drug delivery cloud.

The system 10 can be used to easily repeat an assessment procedure and then determine the statistical variation between the results of the repeated procedures. The simple, reliable and robust technology allows an  
30 assessment to be completed quickly and for a statistically significant number of assessments to be completed in a short period of time (hours).

10

The processor 28 may be programmed to quantify the variation in the quantitative indications of the efficiency of the drug delivery process and/or of the drug delivery cloud. For example, the processor 28 may store the determined fine particle fraction for each drug delivery assessment in the memory 27. After a number of assessments, the processor 28 can perform statistical analysis on the sample of fine particle fractions stored. It may, for example, provide the mean fine particle fraction and the standard deviation from the mean. Alternatively, the processor 28 may store the separate measurement profiles or characteristic parameters for each assessment and average them before using the average to provide indications of the efficiency of the drug delivery process and/or of the drug delivery cloud.

The system 10 comprises three distinct components which are very important to the drug delivery process: the drug delivery device 12, the pulmonary drug formulation 14 and the physiological actuator 16.

The system 10 allows the efficiency of a new drug delivery device to be assessed by controlling the physiological actuation by using a breathing simulator and by using a sample of material with known properties as the drug formulation 14.

The system 10 allows the efficiency of a new drug formulation to be assessed by controlling the physiological actuation by using a breathing simulator and by using a standard drug delivery device 12.

The system 10 allows the assessment of self-administration of a pulmonary drug 14 by a person using a drug delivery device 12. The device may indicate whether a user needs to inhale harder or softer. The system may be used with a placebo drug to train a person how to use a pulmonary drug delivery device.

Fig. 3 illustrates an alternative embodiment of the assessment system 10. Where the same reference numerals are shared with Fig. 2 they indicate the same components. The system 10 has a different measurement device 20.

5

The measurement device 20 has a plurality of sensors  $24_1, 24_2 \dots$ . In this example, two sensors are illustrated but more than two sensors may be used.

10 A first sensor  $24_1$ , includes a first radiation source  $25_1$  and a first radiation detector  $26_1$  lying in a first plane perpendicular to the longitudinal axis of the tube 22 and the flow direction F. The first plane is located at position  $x_1$  along the longitudinal axis of the tube 22.

15 A second sensor  $24_2$ , includes a second radiation source  $25_2$  and a second radiation detector  $26_2$  lying in a second plane perpendicular to the longitudinal axis of the tube 22 and the flow direction F. The second plane is located at position  $x_2$  along the longitudinal axis of the tube 22.

20 In this example, the sensors  $24_n$  operate by obscuration of light and the light source  $25_n$  and light detector  $26_n$  are positioned diametrically opposite each other. In other embodiments, the sensors  $24_n$  operate by light scattering and while the source and detector are still positioned in the same plane, the detector is not positioned in the 'line-of-sight' of the light source so that it  
25 detects light at a predetermined scattering angle.

The processor 28 records in memory 27 a first measurement profile from the first sensor  $24_1$  and a second measurement profile from the second sensor  $24_2$  during a drug delivery. An illustrative first measurement profile M1  
30 and a second measurement profile M2 are shown in Fig 4. The processor 28 independently processes the first measurement profile M1 and the second measurement profile M2 as described above to produce a first set of

quantitative values for characteristic parameters from the first measurement profile and a second set of quantitative values for characteristic parameters from the second measurement profile.

5        The quantitative values of the first set of parameters characterising the shape of the first measurement profile provide quantitative indications of the efficiency of the drug delivery process and/or status of the drug delivery cloud at position  $x_1$ .

10       The quantitative values of the second set of parameters characterising the shape of the second measurement profile provide quantitative indications of the efficiency of the drug delivery process and/or status of the drug delivery cloud at position  $x_2$ .

15       A comparison of the first measurement profile or results obtained from the first measurement profile with the second measurement profile or the results obtained from the second measurement profile provide information on the dynamics of the drug cloud. For example, the evaporation of propellant in a liquid delivery system may result in an increase in the maximum amplitude  
20       from the first measurement to the second measurement response.

      The processor 28 is arranged to cross-correlate the first measurement profile with the second measurement profile to obtain a time off-set  $T$  between the profiles. The dose functions  $P_{dose}$  may be cross correlated instead of the  
25       measurement profiles. The distance between  $x_1$  and  $x_2$  is stored in memory 27 and is divided by the time off-set  $T$  by the processor 28, to obtain an indication of the average speed of the drug cloud through the tube 22. The speed of the drug cloud gives an indication of the percentage of the drug cloud that will be deposited on the back of the throat. The processor 28 is arranged to provide  
30       the indication of the average speed via the output 29.

Another alternative embodiment of the assessment system 10 uses one or more sensors that detect light at different frequencies. The pulmonary drug 14 for delivery includes pharmacologically inactive large carrier particles (e.g. lactose) coloured with a first colour and coated with a pharmacologically

5 active drug coloured a second colour. The drug is designed to leave the carrier in transit. As it does so the proportion of the second colour detected increases and the fine particle fraction for the second colour increases. The effectiveness of the drug release from the carrier can therefore be  
10 determined.

Although the measurement device 20 has been described as a separate add-on component to the drug delivery device 12, in other embodiments the functionality of the measurement device 20 may be  
15 integrated into the drug delivery device 12.

Fig. 5 illustrates a multi-dose drug delivery device 12. A user of the device self administers the correct dose by performing a plurality of inhalations using the device. Each inhalation causes a drug delivery to the  
20 user. The device automatically varies the amount of drug delivered in each drug delivery and/or the number of drug deliveries required. This is particularly useful if the user has little or variable wind and cannot inhale forcefully or consistently.

25 The functionality of the measurement device 20 is integrated into the drug delivery device 12.

The device 12 has a metering unit 40 which meters the amount of drug that is available for drug delivery on inhalation. The metering unit 40 receives  
30 an input from the processor 28.

On a first inhalation, a predetermined amount of drug is released by the metering unit 40. The sensor 24 detects the variation in radiation detected by the radiation detector 26 as the inhaled drug cloud passes between the radiation source 25 and radiation detector 26. The processor 28 records the measurement profile in the memory 27 and then processes the measurement profile as described above to determine the fine particle fraction and/or dose of the inhaled first dose.

The processor then controls the amount of drug released by the metering unit 40 for the subsequent drug delivery on the next inhalation. Alternatively, or in addition, the processor may determine whether and how many additional drug delivery inhalations are required. An adaptive feedback system is thus created that controls, in dependence upon the effectiveness of the drug delivery in the preceding inhalation, the amount of drug to be released in a subsequent inhalation or inhalations. The effectiveness of the drug delivery in the preceding inhalation may be determined from the characteristic(s) of a detected measurement profile when a single detector is used or from a comparison of the measurement profiles from separate detectors when two or more detectors are used.

Although embodiments of the present invention have been described in the preceding paragraphs with reference to various examples, it should be appreciated that modifications to the examples given can be made without departing from the scope of the invention as claimed.

Whilst endeavouring in the foregoing specification to draw attention to those features of the invention believed to be of particular importance it should be understood that the Applicant claims protection in respect of any patentable feature or combination of features hereinbefore referred to and/or shown in the drawings whether or not particular emphasis has been placed thereon.

Claims

- 5 1. A method of assessing the effectiveness of pulmonary drug delivery, comprising the steps of:
- a) providing a drug into an air flow past a sensor comprising a radiation source and a radiation detector;
  - b) detecting, at the radiation detector, incident radiation over a period  
10 of time as a measurement profile;
  - c) quantifying at least one characteristic of the shape of a measurement profile; and
  - d) producing an indication of the effectiveness of pulmonary drug delivery based upon the at least one quantified characteristic.
- 15 2. A method as claimed in any preceding claim wherein the indication of the effectiveness of pulmonary drug delivery quantifies the amount of fine particles in the delivered pulmonary drug.
- 20 3. A method as claimed in any preceding claim, wherein the indication of the effectiveness of pulmonary drug delivery is a quantitative measure of the effectiveness of the pulmonary drug delivery.
- 25 4. A method as claimed in claim 1, 2 or 3 for the in-situ assessment of the effectiveness of pulmonary drug delivery, wherein the step of providing a drug involves the release of the drug from a drug delivery device and a breathing simulator provides the air flow.
- 30 5. A method as claimed in claim 1, 2 or 3 for the in-vivo assessment of the effectiveness of pulmonary drug delivery, wherein the step of providing a drug involves the release of the drug from a drug delivery device and the air flow is provided by a person's breath in-take.



6. A method as claimed in any preceding claim, wherein the indication of the effectiveness of pulmonary drug delivery is based upon a single measurement profile.

7. A method as claimed in any one of claims 1 to 5, wherein the indication of the effectiveness of pulmonary drug delivery is based upon a plurality of measurement profiles.

10

8. A method as claimed in claim 7, comprising the steps of:  
repeatedly providing a drug into an air flow past a sensor comprising a radiation source and a radiation detector and detecting, at the radiation detector, incident radiation over a period of time as a measurement profile;

15 quantifying at least one characteristic of the shape of each of the plurality of detected measurement profiles; and

producing the indication of the effectiveness of pulmonary drug delivery based upon the plurality of at least one quantified characteristics.

20 9. A method as claimed in claim 7 or 8, wherein the indication of the effectiveness of pulmonary drug delivery includes an average.

10. A method as claimed in claim 7, 8 or 9, wherein the indication of the effectiveness of pulmonary drug delivery includes a measure of the variance in the effectiveness of pulmonary drug delivery.

25

11. A method as claimed in any preceding claim further comprising the steps of:

30 assessing the fine particle dose delivered from a first quantified characteristic of the shape of the measurement profile;

assessing the total dose delivered from a second, different, quantified characteristic of the shape of the measurement profile; and

using the assessment of the fine particle dose delivered and the assessment of the total dose delivered to provide an indication of the effectiveness of pulmonary drug delivery.

5 12. A method as claimed in claim 11, wherein the indication of the effectiveness of pulmonary drug delivery is the fine particle fraction of the dose delivered.

10 13. A method as claimed in any one of claims 11 or 12, wherein the first characteristic is the height of the measurement profile or the height of a curve fitted to the measurement profile.

15 14. A method as claimed in any one of claims 11, 12 or 13, wherein the second characteristic involves the normalised integration of the measurement profile over its width or the normalised integration of a curve fitted to the measurement profile over its width.

20 15. A method as claimed in claim 13 or 14, wherein the curve fitted to the measurement profile is a dose function which when summed with a level transition residual function substantially re-creates the measurement profile.

16. A method as claimed in any one of claims 11 to 15, wherein the quantifying and assessment steps occur automatically in situ.

25 17. A method as claimed in any preceding claim further comprising the step of converting the indication of the effectiveness of pulmonary drug delivery based upon the at least one quantified characteristic to a measurement of the effectiveness of pulmonary drug delivery using calibration data.

30 18. A method as claimed in any preceding claim wherein steps b), c) and d) occur within a measurement device.

19. A method as claimed in any one of claims 1 to 17, wherein steps a), b), c) and d) occur within a drug delivery device.
- 5 20. A measurement device for assessing the effectiveness of pulmonary drug delivery, comprising:
- a conduit through which air carrying a cloud of drug particles can flow during drug delivery;
  - a radiation source for providing radiation into the conduit;
  - 10 a radiation detector for detecting radiation from the conduit over a period of time as a measurement profile; and
  - a processor operable to quantify one or more characteristics of the shape of a measurement profile and to produce an indication of the effectiveness of pulmonary drug delivery based upon the quantified
  - 15 characteristic(s).
21. A measurement device as claimed in claim 20, arranged for releasable attachment to a drug dispensing device.
- 20 22. A measurement device as claimed in claim 20, integrated within a drug delivery device.
23. A measurement device as claimed in claim 20, 21 or 22, wherein the indication of the effectiveness of pulmonary drug delivery indicates the fine
- 25 particle component of the delivered pulmonary drug.
24. A measurement device as claimed in any one of claims 20 to 23 further comprising a memory for storing at least one measurement profile.
- 30 25. A measurement device as claimed in any one of claims 20 to 24, wherein the processor is operable to produce an indication of the

effectiveness of pulmonary drug delivery based upon the quantified characteristic(s) obtained from multiple measurement profiles.

26. A measurement device as claimed in claim 25, wherein the indication  
5 of the effectiveness of pulmonary drug delivery includes an average.

27. A measurement device as claimed in claim 25 or 26, wherein the  
indication of the effectiveness of pulmonary drug delivery includes a  
measurement of variance.  
10

28. A measurement device as claimed in any one of claims 20 to 27  
wherein the indication of the effectiveness of pulmonary drug delivery is a  
quantitative indication.

15 29. A measurement device as claimed in any one of claims 20 to 28,  
wherein the processor is operable to determine the fine particle dose  
delivered from a first quantified characteristic of the shape of a measurement  
profile and to determine the total dose delivered from a second quantified  
characteristic of the shape of the same measurement profile.

20 30. A measurement device as claimed in claim 29, wherein the processor  
is operable to use the determined fine particle dose delivered and the  
determined the total dose delivered to calculate an indication of the  
effectiveness of pulmonary drug delivery.

25 31. A measurement device as claimed in claim 30, wherein the indication  
of the effectiveness of pulmonary drug delivery is the fine particle fraction of  
the dose delivered.

30 32. A measurement device as claimed in any one of claims 29 or 31,  
wherein the first characteristic is the height of the measurement profile or the  
height of a curve fitted to the measurement profile.

33. A measurement device as claimed in any one of claims 29 to 32,  
wherein the second characteristic involves the normalised integration of the  
measurement profile over its width or the normalised integration of a curve  
5 fitted to the measurement profile over its width.

34. A measurement device as claimed in claim 32 or 33, wherein the  
processor is operable to fit a dose function curve to a measurement profile,  
wherein the summation of the dose function curve with a level transition  
10 residual function substantially re-creates the measurement profile.

35. A measurement device as claimed in any one of claims 20 to 34  
wherein the operations of the processor are automatic.

15 36. A measurement device as claimed in any one of claims 20 to 34  
wherein the operations of the processor are in real-time.

37. A measurement device as claimed in any one of claims 20 to 34  
comprising a second radiation detector for detecting radiation from the conduit  
20 over a period of time as a second measurement profile, wherein the processor  
is operable to produce an indication of the effectiveness of pulmonary drug  
delivery based upon a plurality of measurement profiles for a single drug  
delivery.

25 38. A measurement device as claimed in claim 37, further comprising a  
second radiation source.

39. A method of assessing the effectiveness of pulmonary drug delivery,  
comprising the steps of:  
30 recording, during a drug delivery, the output of a first radiation detector  
against time as a first measurement profile;

recording, during the same drug delivery, the output of a second radiation detector against time as a second measurement profile; and

processing the first and second measurement profiles to produce an indication of the effectiveness of pulmonary drug delivery.

5

40. A method as claimed in claim 39, wherein the processing involves a quantitative comparison of the two measurement profiles.

41. A method as claimed in claim 39, wherein the processing involves the cross-correlation of the two measurement profiles.

10

42. A method as claimed in claim 39, 40 or 41, wherein the indication of the effectiveness of pulmonary drug delivery is the speed of a drug cloud during the drug delivery.

15

43. A method as claimed in any one of claims 39 to 42, wherein the first and second radiation detectors are located at different positions along a drug flow path.

44. A method as claimed in any one of claims 39 to 42, wherein the first and second radiation detectors are arranged to detect radiation at different energies.

20

45. A measurement device for assessing the effectiveness of pulmonary drug delivery, comprising:

25

a conduit through which air carrying a cloud of drug particles can flow during drug delivery;

a radiation source for providing radiation into the conduit;

a first radiation detector for detecting radiation from the conduit over a period of time as a first measurement profile;

30

a second radiation detector for detecting radiation from the conduit over the period of time as a second measurement profile; and

a processor operable to produce an indication of the effectiveness of pulmonary drug delivery based upon the first and second measurement  
5 profiles.

46. A drug delivery device for providing a drug dose to a user in a plurality of separate drug deliveries, comprising:

a drug metering means for releasing a controlled amount of drug for  
10 each drug delivery;

a conduit through which air carrying a cloud of drug particles can flow;

a radiation source for providing radiation into the conduit;

a first radiation detector for detecting radiation from the conduit during a on-going drug delivery as a first measurement profile; and

15 control means operable to control the drug metering means, for a subsequent drug delivery, in dependence upon at least the first measurement profile.

47. A drug delivery device as claimed in claim 46, wherein the control  
20 means is operable to control the drug metering means, for a subsequent drug delivery, in dependence upon an indication of the effectiveness of the on-going drug delivery.

48. A drug delivery device as claimed in claim 47, wherein the indication of  
25 the effectiveness of the on-going drug delivery is based upon one or more quantified characteristic(s) of the shape of the measurement profile.

49. A drug delivery device as claimed in claim 47, further comprising a  
30 second radiation detector for detecting radiation from the conduit during the on-going drug delivery as a second measurement profile, wherein the indication of the effectiveness of the on-going drug delivery is based upon the first and second measurement profiles.

50. A drug delivery device as claimed in any one of claims 46 to 49,  
wherein the drug metering means is arranged to vary the amount of drug  
released in a subsequent drug delivery, in dependence upon at least the first  
5 measurement profile.

51. A drug delivery device as claimed in any one of claims 46 to 50,  
wherein the drug metering means is arranged to vary the number of drug  
deliveries required in dependence upon at least the first measurement profile.  
10



52. A method of assessing the effectiveness of fine particle delivery,  
comprising the steps of:

- a) providing an air flow comprising particles past a sensor comprising  
a radiation source and a radiation detector;
- 15 b) detecting, at the radiation detector, incident radiation over a period  
of time as a measurement profile;
- c) quantifying at least one characteristic of the shape of a  
measurement profile; and
- d) producing an indication of the effectiveness of fine particle delivery  
20 based upon the at least one quantified characteristic.


53. A method, device or system substantially as hereinbefore described  
with reference to and/or as shown in the accompanying drawings.

25 54. Any novel subject matter or combination including novel subject matter  
disclosed, whether or not within the scope of or relating to the same invention  
as the preceding claims.







## File 2




**Fig. 3**



**Fig. 4**

3/3

**FIG. 5**

# INTERNATIONAL SEARCH REPORT

national Application No  
T/GB2004/001714

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7    A61M15/00    A61B5/097		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7    A61M    A61B		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 824 023 A (MICROFLOW ENG SA) 18 February 1998 (1998-02-18) column 5, line 42 - line 53; claim 1 column 9, line 8 - line 28 column 10, line 42 - line 54 column 11, line 2 - line 22; figures 4-7, 14	20-38, 45-51
A	WO 02/34318 A (BONNEY STANLEY GEORGE ;DAVIES MICHAEL BIRSHA (GB); GLAXO GROUP LTD) 2 May 2002 (2002-05-02) page 2, line 27 -page 6, line 2 page 11, line 19 -page 13, line 30	20-38, 45-51
A	US 5 404 871 A (GOODMAN DAVID E ET AL) 11 April 1995 (1995-04-11) abstract	20-38, 45-51
-/-		
<div style="display: flex; justify-content: space-between;"> <span><input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.</span> <span><input checked="" type="checkbox"/> Patent family members are listed in annex.</span> </div>		
<div style="display: flex;"> <div style="flex: 1;"> <p>* Special categories of cited documents:</p> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*G* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search	Date of mailing of the international search report	
31 August 2004	08/09/2004	
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer  Rodríguez Cossío, J	

# INTERNATIONAL SEARCH REPORT

International Application No  
/GB2004/001714

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 02/24264 A (MICRODRUG AG ;NILSSON THOMAS (SE)) 28 March 2002 (2002-03-28) the whole document -----	20-38, 45-51

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box II.2

Claims Nos.: 53,54

The wording of claims 53 and 54 is obscure and ambiguous, being impossible to determine the subject-matter to which they refer.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB2004/001714

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-19, 39-44, 52  
because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☒ Claims Nos.: 53, 54  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No  
r/GB2004/001714

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0824023	A	18-02-1998	EP 0824023 A1	18-02-1998
WO 0234318	A	02-05-2002	AU 1825002 A	15-05-2002
			AU 2302802 A	06-05-2002
			AU 2509901 A	18-06-2001
			WO 0234318 A2	02-05-2002
			WO 0236188 A2	10-05-2002
			EP 1235606 A1	04-09-2002
			EP 1326668 A2	16-07-2003
			EP 1330282 A2	30-07-2003
			JP 2003516197 T	13-05-2003
			JP 2004512101 T	22-04-2004
			JP 2004512146 T	22-04-2004
			WO 0141846 A1	14-06-2001
			US 2003079744 A1	01-05-2003
			US 2004050385 A1	18-03-2004
US 5404871	A	11-04-1995	AT 188617 T	15-01-2000
			CA 2082168 C	26-03-1996
			DE 69230546 D1	17-02-2000
			DE 69230546 T2	21-06-2000
			DK 529053 T3	19-06-2000
			EP 0529053 A1	03-03-1993
			ES 2141104 T3	16-03-2000
			JP 3349354 B2	25-11-2002
			JP 9164205 A	24-06-1997
			JP 2613347 B2	28-05-1997
			JP 5506598 T	30-09-1993
			US 5394866 A	07-03-1995
			US 5469750 A	28-11-1995
			US 5450336 A	12-09-1995
			US 5392768 A	28-02-1995
			WO 9215353 A2	17-09-1992
			US 5522378 A	04-06-1996
			US 5542410 A	06-08-1996
			US 5622162 A	22-04-1997
			US 5497764 A	12-03-1996
			US 5520166 A	28-05-1996
			US 5608647 A	04-03-1997
			US 5655516 A	12-08-1997
			US 5743252 A	28-04-1998
			US 5755218 A	26-05-1998
			US 5813397 A	29-09-1998
			US 5826570 A	27-10-1998
WO 0224264	A	28-03-2002	SE 517225 C2	14-05-2002
			AU 9041001 A	02-04-2002
			BR 0113994 A	12-08-2003
			CA 2418189 A1	28-03-2002
			CN 1462196 T	17-12-2003
			EP 1322361 A1	02-07-2003
			JP 2004508899 T	25-03-2004
			SE 0003364 A	22-03-2002
			WO 0224264 A1	28-03-2002
			US 6571793 B1	03-06-2003